{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:41:47Z","timestamp":1792813307004,"version":"4.5.0"},"reference-count":47,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,10,23]]},"DOI":"10.1253\/circj.cj-26-0356","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:12:03Z","timestamp":1791583923000},"page":"1573-1580","source":"Crossref","is-referenced-by-count":0,"title":["Phenotyping Heart Failure With Preserved Ejection Fraction in Japan\u3000\u2015 Position Paper on Current Evidence and Future Directions \u2015"],"prefix":"10.1253","volume":"90","author":[{"given":"Yasushi","family":"Sakata","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kyodo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nara Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yasumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Amagasaki Chuo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine"},{"name":"Department of Medical Informatics, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sotomi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Hikoso","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nara Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure. <i>Circ J<\/i> 2025; 89: 1278\u20131444, doi:10.1253\/circj.CJ-25-0002.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Li R, Liu Y, Zhao Z, Zhang C, Dong W, Qi Y, et al. Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction. <i>eClinicalMedicine<\/i> 2025; 88: 103462, doi:10.1016\/j.eclinm.2025.103462.","DOI":"10.1016\/j.eclinm.2025.103462"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>Eur J Heart Fail<\/i> 2015; 17: 925\u2013935, doi:10.1002\/ejhf.327.","DOI":"10.1002\/ejhf.327"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction: A report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. <i>Circ J<\/i> 2018; 82: 1534\u20131545, doi:10.1253\/circj.CJ-18-0073.","DOI":"10.1253\/circj.CJ-18-0073"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Obokata M, Sorimachi H, Harada T, Kagami K, Saito Y, Ishii H. Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan. <i>J Card Fail<\/i> 2023; 29: 375\u2013388, doi:10.1016\/j.cardfail.2022.09.018.","DOI":"10.1016\/j.cardfail.2022.09.018"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Sorimachi H, Obokata M, Omote K, Reddy YNV, Burkhoff D, Shah SJ, et al. Racial differences of cardiac structure and function in heart failure with preserved ejection fraction. <i>J Card Fail<\/i> 2025; 31: 624\u2013634, doi:10.1016\/j.cardfail.2024.08.042.","DOI":"10.1016\/j.cardfail.2024.08.042"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, et al. Heart failure with preserved ejection fraction in Asia. <i>Eur J Heart Fail<\/i> 2019; 21: 23\u201336, doi:10.1002\/ejhf.1227.","DOI":"10.1002\/ejhf.1227"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, et al. Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). <i>Circ J<\/i> 2021; 85: 1438\u20131450, doi:10.1253\/circj.CJ-20-0947.","DOI":"10.1253\/circj.CJ-20-0947"},{"key":"9","unstructured":"9. Nakagawa A, Yasumura Y, Yamada T, Uematsu M, Abe H, Nakagawa Y, et al. Specialized phenotyping algorithm for Japanese HFpEF patients is needed for effective treatment and prognostic estimation: Learnings from the PURSUIT-HFpEF registry. <i>Shinzo<\/i> 2020; 52: 1002\u20131010, doi:10.11281\/shinzo.52.1002."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Sotomi Y, Hikoso S, Komukai S, Sato T, Oeun B, Kitamura T, et al. Phenotyping of acute decompensated heart failure with preserved ejection fraction. <i>Heart<\/i> 2022; 108: 1553\u20131561, doi:10.1136\/heartjnl-2021-320270.","DOI":"10.1136\/heartjnl-2021-320270"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Matsuoka Y, Sotomi Y, Nakatani D, Okada K, Sunaga A, Kida H, et al. Phenotypic trajectories from acute to stable phase in heart failure with preserved ejection fraction: Insights from the PURSUIT-HFpEF study. <i>J Am Heart Assoc<\/i> 2025; 14: e037567, doi:10.1161\/JAHA.124.037567.","DOI":"10.1161\/JAHA.124.037567"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Nakano K, Nochioka K, Yasuda S, Tamori D, Shiroto T, Sato Y, et al. Machine learning approach to stratify complex heterogeneity of chronic heart failure: A report from the CHART-2 study. <i>ESC Heart Fail<\/i> 2023; 10: 1597\u20131604, doi:10.1002\/ehf2.14288.","DOI":"10.1002\/ehf2.14288"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Kyodo A, Kanaoka K, Keshi A, Nogi M, Nogi K, Ishihara S, et al. Heart failure with preserved ejection fraction phenogroup classification using machine learning. <i>ESC Heart Fail<\/i> 2023; 10: 2019\u20132030, doi:10.1002\/ehf2.14368.","DOI":"10.1002\/ehf2.14368"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Nakamaru R, Shiraishi Y, Niimi N, Kohno T, Nagatomo Y, Takei M, et al. Phenotyping of elderly patients with heart failure focused on noncardiac conditions: A latent class analysis from a multicenter registry of patients hospitalized with heart failure. <i>J Am Heart Assoc<\/i> 2023; 12: e027689, doi:10.1161\/JAHA.122.027689.","DOI":"10.1161\/JAHA.122.027689"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Saito Y, Omae Y, Harada T, Sorimachi H, Yuasa N, Kagami K, et al. Exercise stress echocardiography-based phenotyping of heart failure with preserved ejection fraction. <i>J Am Soc Echocardiogr<\/i> 2024; 37: 759\u2013768, doi:10.1016\/j.echo.2024.05.003.","DOI":"10.1016\/j.echo.2024.05.003"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Tatsuta D, Nakao M, Nagai T, Mizuguchi Y, Yokota I, Koya T, et al. Clinical phenotyping and treatment response in patients with chronic heart failure. <i>JACC Adv<\/i> 2025; 4: 101972, doi:10.1016\/j.jacadv.2025.101972.","DOI":"10.1016\/j.jacadv.2025.101972"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Suna S, Hikoso S, Yamada T, Uematsu M, Yasumura Y, Nakagawa A, et al. Study protocol for the PURSUIT-HFpEF study: A prospective, multicenter, observational study of patients with heart failure with preserved ejection fraction. <i>BMJ Open<\/i> 2020; 10: e038294, doi:10.1136\/bmjopen-2020-038294.","DOI":"10.1136\/bmjopen-2020-038294"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H. Trend of Westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. <i>Circ J<\/i> 2011; 75: 823\u2013833, doi:10.1253\/circj.cj-11-0135.","DOI":"10.1253\/circj.CJ-11-0135"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Ishihara S, Kawakami R, Nogi M, Hirai K, Hashimoto Y, Nakada Y, et al. Incidence and clinical significance of 30-day and 90-day rehospitalization for heart failure among patients with acute decompensated heart failure in Japan: From the NARA-HF Study. <i>Circ J<\/i> 2020; 84: 194\u2013202, doi:10.1253\/circj.CJ-19-0620.","DOI":"10.1253\/circj.CJ-19-0620"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Yamazaki Y, Shiraishi Y, Kohsaka S, Nagatomo Y, Fukuda K, Kohno T, et al. Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan. <i>Sci Rep<\/i> 2021; 11: 19360, doi:10.1038\/s41598-021-98173-8.","DOI":"10.1038\/s41598-021-98173-8"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Naito A, Kagami K, Yuasa N, Harada T, Sorimachi H, Murakami F, et al. Prognostic utility of cardiopulmonary exercise testing with simultaneous exercise echocardiography in heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2024; 26: 2582\u20132590, doi:10.1002\/ejhf.3334.","DOI":"10.1002\/ejhf.3334"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2019; 40: 3297\u20133317, doi:10.1093\/eurheartj\/ehz641.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Nakao M, Nagai T, Tada A, Koya T, Ishizaka S, Mizuguchi Y, et al. Prognostic value of reticulocyte production ability in patients with chronic heart failure. <i>Can J Cardiol<\/i> 2025; 41: 1274\u20131284, doi:10.1016\/j.cjca.2025.02.004.","DOI":"10.1016\/j.cjca.2025.02.004"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Peters AE, Tromp J, Shah SJ, Lam CSP, Lewis GD, Borlaug BA, et al. Phenomapping in heart failure with preserved ejection fraction: Insights, limitations, and future directions. <i>Cardiovasc Res<\/i> 2022; 118: 3403\u20133415, doi:10.1093\/cvr\/cvac179.","DOI":"10.1093\/cvr\/cvac179"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Okuno T, Kagami K, Harada T, Hoshiga M, Ishii H, Obokata M. Diagnostic approaches to heart failure with preserved ejection fraction (HFpEF): Identification of unrecognized HFpEF. <i>Circ J<\/i> 2025; 89: 877\u2013884, doi:10.1253\/circj.CJ-25-0214.","DOI":"10.1253\/circj.CJ-25-0214"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. <i>N Engl J Med<\/i> 2022; 387: 1089\u20131098, doi:10.1056\/NEJMoa2206286.","DOI":"10.1056\/NEJMoa2206286"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. <i>N Engl J Med<\/i> 2021; 385: 1451\u20131461, doi:10.1056\/NEJMoa2107038.","DOI":"10.1056\/NEJMoa2107038"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. <i>N Engl J Med<\/i> 2024; 391: 1475\u20131485, doi:10.1056\/NEJMoa2407107.","DOI":"10.1056\/NEJMoa2407107"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. <i>N Engl J Med<\/i> 2023; 389: 1069\u20131084, doi:10.1056\/NEJMoa2306963.","DOI":"10.1056\/NEJMoa2306963"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. <i>N Engl J Med<\/i> 2025; 392: 427\u2013437, doi:10.1056\/NEJMoa2410027.","DOI":"10.1056\/NEJMoa2410027"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Martens P, Augusto SN Jr, Erzeel J, Pison L, Mullens W, Tang WHW. Effects of atrial fibrillation ablation for heart failure with preserved ejection fraction: Insights from CABANA. <i>JACC Heart Fail<\/i> 2025; 13: 785\u2013794, doi:10.1016\/j.jchf.2025.01.029.","DOI":"10.1016\/j.jchf.2025.01.029"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Tanaka A. Cardiovascular, kidney, and metabolic network medicine: Past, present, and future challenges and directions. <i>Circ J<\/i> 2026; 90: 449\u2013457, doi:10.1253\/circj.CJ-26-0129.","DOI":"10.1253\/circj.CJ-26-0129"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. <i>Hypertension<\/i> 2018; 71: 599\u2013608, doi:10.1161\/HYPERTENSIONAHA.117.10360.","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. McDiarmid AK, Swoboda PP, Erhayiem B, Bounford KA, Bijsterveld P, Tyndall K, et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. <i>J Am Heart Assoc<\/i> 2020; 9: e011521, doi:10.1161\/JAHA.118.011521.","DOI":"10.1161\/JAHA.118.011521"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction. <i>JACC Heart Fail<\/i> 2020; 8: 172\u2013184, doi:10.1016\/j.jchf.2019.09.009.","DOI":"10.1016\/j.jchf.2019.09.009"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Sotomi Y, Hikoso S, Nakatani D, Okada K, Dohi T, Sunaga A, et al. Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model. <i>Heart<\/i> 2023; 109: 1231\u20131240, doi:10.1136\/heartjnl-2022-322181.","DOI":"10.1136\/heartjnl-2022-322181"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory\u2013metabolic phenotype of heart failure with a preserved ejection fraction: A hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>Eur J Heart Fail<\/i> 2020; 22: 1551\u20131567, doi:10.1002\/ejhf.1902.","DOI":"10.1002\/ejhf.1902"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2019; 381: 1609\u20131620, doi:10.1056\/NEJMoa1908655.","DOI":"10.1056\/NEJMoa1908655"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Izumi K, Utsunomiya H, Takeuchi M, Hamada A, Hyodo Y, Mogami A, et al. Relationship between duration of atrial fibrillation and right heart structure remodeling as assessed by 3-dimensional transesophageal echocardiography. <i>Int J Cardiol<\/i> 2024; 399: 131667, doi:10.1016\/j.ijcard.2023.131667.","DOI":"10.1016\/j.ijcard.2023.131667"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Gorter TM, van Melle JP, Rienstra M, Borlaug BA, Hummel YM, van Gelder IC, et al. Right heart dysfunction in heart failure with preserved ejection fraction: The impact of atrial fibrillation. <i>J Card Fail<\/i> 2018; 24: 177\u2013185, doi:10.1016\/j.cardfail.2017.11.005.","DOI":"10.1016\/j.cardfail.2017.11.005"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. <i>JAMA<\/i> 2013; 309: 1268\u20131277, doi:10.1001\/jama.2013.2024.","DOI":"10.1001\/jama.2013.2024"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: A randomized open-label pilot study. <i>BMC Cardiovasc Disord<\/i> 2020; 20: 408, doi:10.1186\/s12872-020-01671-2.","DOI":"10.1186\/s12872-020-01671-2"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. <i>N Engl J Med<\/i> 2023; 388: 1833\u20131842, doi:10.1056\/NEJMoa2300525.","DOI":"10.1056\/NEJMoa2300525"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. McDonagh J, Ferguson C, Hilmer SN, Hubbard RE, Lindley RI, Driscoll A, et al. An expert opinion on the management of frailty in heart failure from the Australian Cardiovascular Alliance National Taskforce. <i>Heart Lung Circ<\/i> 2025; 34: 693\u2013703, doi:10.1016\/j.hlc.2025.01.012.","DOI":"10.1016\/j.hlc.2025.01.012"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Hirashiki A, Shimizu A. Cardiac rehabilitation and heart failure with preserved ejection fraction. <i>Circ Rep<\/i> 2025; 7: 837\u2013841, doi:10.1253\/circrep.CR-25-0130.","DOI":"10.1253\/circrep.CR-25-0130"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. Nakagaito M, Imamura T, Izumida T, Nakamura M, Kinugawa K. Sodium\u2013glucose cotransporter 2 inhibitors in underweight patients with heart failure: A case series. <i>J Clin Med<\/i> 2026; 15: 2027, doi:10.3390\/jcm15052027.","DOI":"10.3390\/jcm15052027"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Nakano K, Kanenawa K, Isotani A, Morinaga T, Yamamoto K, Miyawaki N, et al. The efficacy and safety of sodium\u2013glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure. <i>ESC Heart Fail<\/i> 2025; 12: 2087\u20132097, doi:10.1002\/ehf2.15218.","DOI":"10.1002\/ehf2.15218"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/11\/90_CJ-26-0356\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:23:29Z","timestamp":1792812209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/11\/90_CJ-26-0356\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-26-0356","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"article-number":"CJ-26-0356"}}